Skip to main content
Explore URMC
menu

IGIH19161, Hezel, NuTide:121, Hepatoboliary, NUC-1031

Research Question:
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.

Basic Study Information

Purpose:
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care

Location: University of Rochester Medical Center
Study Reference #: IGIH19161

Lead Researcher (Principal Investigator)

Lead Researcher:  Aram Hezel

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Return to Search